PERSON – Page 4

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

2 weeks ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

2 weeks ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

2 weeks ago talkbio0Tagged * * New Rhein Healthcare Investors, * * Sanofi Capital, ALV-100, ALV-200, Alveus Therapeutics, Amylin, Andera Partners, Antagonist muscle action, GIPR gene, MariTide-like, Metabolic Diseases, Obesity, Omega Funds, Product containing glucagon-like peptide 1 receptor agonist (product), Series

Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

2 weeks ago talkbio0Tagged AstraZeneca, Biological Factors, Head of US, Investments, President brand of dental material, Rick R. Suarez, Surgical aspects, U.S., Virginia manufacturing facility, Wilmington Delaware

AstraZeneca; Rick R. Suarez; US President; Head of US BioPharmaceuticals Business Unit; $50 billion US investment; Virginia manufacturing facility; US operations; biopharmaceuticals; revenue goal 2030; Wilmington Delaware

Independent expert group to review HPV vaccine evidence after US recommendation change

2 weeks ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Childhood, CIDRAP, disbanded, Gardasil, HPV vaccine, Immunization Schedule, independent review, recommendation change, single-dose schedule, U.S., Vaccine Integrity Project

HPV vaccine; Vaccine Integrity Project; independent review; CDC recommendation change; single-dose schedule; ACIP disbanded; CIDRAP; Robert F. Kennedy Jr.; US childhood immunization schedule; Gardasil

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

2 weeks ago talkbio0Tagged AI-driven, biotherapeutics, Country, developability, Drug Kinetics, Evotec SE, Financial cost, funding grant, Gates Foundation * *, Global Health, HIV, Immunogenicity (package insert), J.MD, low, Malaria, manufacturability, Manufactured Supplies, middle-income, Monoclonal Antibodies, Optimization, Platform, Respiratory syncytial virus, Stable status, Titer

Evotec SE; Gates Foundation; grant; J.MD; J.DESIGN platform; AI-driven optimization; monoclonal antibodies; biotherapeutics; developability; manufacturability; stability; immunogenicity; pharmacokinetics; titer; cost of goods; global health; affordable access; low- and middle-income countries; RSV; malaria; HIV